Seller record · Telehealth service

Intimate Rose

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S3, pharmacy identification: No filling pharmacy is named. The weight loss page says compounded medications come from state-licensed compounding pharmacies in the clinician network and refers the buyer to that network's terms and the telehealth consent for pharmacy contact details. 1 more criterion also fails; see the table below.

At a glance

Intimate RoseTelehealth service

6/8criteria passed

Price: Compounded semaglutide or tirzepatide from $169 a month
Sells: compounded semaglutide, compounded tirzepatide, bioidentical HRT
FDA letters: 1 on file

Visit Intimate Rose See all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A North Kansas City, Missouri pelvic health company that sells a GLP-1 weight loss program with compounded semaglutide and tirzepatide, prescribed through the OpenLoop Health clinician network, alongside pelvic health tools, supplements and menopause care. Care starts with a free online evaluation, and no pharmacy is named.

Operating entity No legal entity name appears in the footer, in the terms of service or in the privacy policy, which name the company only as Intimate Rose.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Intimate Rose's weight loss treatment online page
S2	Prescription gating	PASS	Intimate Rose's weight loss treatment online page
S3	Pharmacy identification	FAIL	Intimate Rose's weight loss treatment online page
S4	Compounding disclosure	PASS	Intimate Rose's weight loss treatment online page
S5	Analytical documentation	FAIL	Intimate Rose's weight loss treatment online page; Intimate Rose's terms of service page; Intimate Rose's privacy policy
S6	Business address	PASS	Intimate Rose's privacy policy; Intimate Rose's terms of service page
S7	Price disclosure	PASS	Intimate Rose's weight loss treatment online page
S8	Enforcement status	PASS	FDA's website; FDA warning letter 716458

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSMedical services are provided by OpenLoop Health clinicians, and a licensed provider reviews each health profile and prescribes only if treatment is appropriate.Source: Intimate Rose's weight loss treatment online page.

S2PASSThe weight loss page says care starts with a free evaluation of health history and goals with no payment to get started, followed by a licensed provider's review.Source: Intimate Rose's weight loss treatment online page.

S3FAILNo filling pharmacy is named. The weight loss page says compounded medications come from state-licensed compounding pharmacies in the clinician network and refers the buyer to that network's terms and the telehealth consent for pharmacy contact details.Source: Intimate Rose's weight loss treatment online page.

S4PASSThe weight loss page names compounded semaglutide and tirzepatide and states in several places that compounded medications are not FDA-approved and are not generic versions of Ozempic, Wegovy, Mounjaro or Zepbound.Source: Intimate Rose's weight loss treatment online page.

S5FAILNo certificate of analysis or lot document is published on the weight loss page, the terms of service or the privacy policy.Source: Intimate Rose's weight loss treatment online page; Intimate Rose's terms of service page; Intimate Rose's privacy policy.

S6PASS1419 Murray St, North Kansas City, MO 64116, printed in the privacy policy's contact blocks for Intimate Rose, with the terms giving the same number as Murray Drive.Source: Intimate Rose's privacy policy; Intimate Rose's terms of service page.

S7PASSTreatment plans start at $169 a month, which the page says includes medical oversight, the medication and delivery, with no membership fee.Source: Intimate Rose's weight loss treatment online page.

S8PASSFDA warning letter 716458, September 2025, names Intimate Rose at the North Kansas City, Missouri address its terms print, and it reviewed the seller's own website. It alleges that claims of the same active ingredient as Ozempic, Wegovy, Mounjaro and Zepbound misbranded its compounded semaglutide and tirzepatide. No close-out letter appears in the index. No FDA action has halted the business, and the seller still trades.Source: FDA's website; FDA warning letter 716458.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, bioidentical HRT.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide

Enforcement documents on file: 1 warning letter

FDA warning letter 716458, issued September 2025, to Intimate RoseClaims on the website that compounded semaglutide and tirzepatide have the same active ingredient as Ozempic, Wegovy, Mounjaro and Zepbound are false or misleading and misbrand the products.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Visit Intimate Rose

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.